BACKGROUND: Nonfunctional pituitary adenomas (NFPAs) represent approximately 50% of all pituitary tumors. OBJECTIVE: To evaluate the long-term outcomes of stereotactic radiosurgery for NFPAs. METHODS: We evaluated the management outcomes of Gamma Knife radiosurgery in 125 patients with NFPAs over an interval of 22 years. The median patient age was 54 years (range, 16-88 years). One hundred ten patients (88%) had residual or recurrent tumors after $ 1 surgical procedures, and 17 (14%) had undergone prior fractionated radiation therapy. The median target volume was 3.5 cm 3 (range, 0.4-28.1 cm 3 ), and the median tumor margin dose was 13.0 Gy (range, 10-25 Gy). RESULTS: Tumor volume decreased in 66 patients (53%), remained stable in 46 (37%), and increased in 13 (10.4%) during a median of 62 months (maximum, 19 years) of imaging follow-up. The actuarial tumor control rates at 1, 5, and 10 years were 99%, 94%, and 76%, respectively. Factors associated with a reduced progression-free survival included larger tumor volume ($ 4.5 cm 3 ) and $ 2 prior recurrences. Of 88 patients with residual pituitary function, 21 (24%) suffered new hormonal deficits at a median of 24 months (range, 3-114 months). Prior radiation therapy increased the risk of developing new pituitary hormonal deficits. One patient (0.8%) had a decline in visual function, and 2 (1.6%) developed new cranial neuropathies without tumor progression. CONCLUSION: Stereotactic radiosurgery can provide effective management for patients with newly diagnosed NFPAs and for those after prior resection and/or radiation therapy.
N onfunctional pituitary adenomas represent approximately 50% of all pituitary tumors. Most nonfunctional pituitary adenoma are found because of the development of local mass effect on the visual pathways, endocrine dysfunction, or cranial neuropathy when the tumor extends laterally into the cavernous sinus. Surgical resection, usually by a transsphenoidal route, is considered the first-line management for such patients. Incomplete resection because of regional tumor invasion into surrounding structures (especially the cavernous sinus) may be associated with long-term recurrence rates in as many as 67% of patients. 1, 2 Although additional resection may be attempted for recurrent tumors, complete resection may remain difficult to achieve, and the risks associated with repeat surgery are significantly greater than those for the initial operation. 3 Conventional fractionated radiotherapy (FRT) has been used after subtotal resection to reduce recurrence rates in patients with residual tumors or even in some patients after gross total resection, 1, [4] [5] [6] [7] but there is a growing interest in the use of stereotactic radiosurgery (SRS) to treat these tumors. [8] [9] [10] By delivering highly conformal radiation in a single surgical procedure, SRS potentially provides improved radiobiological tumor control. In addition, the sharp fall of radiation (selectivity) delivered during SRS procedures reduces the long-term risk of adverse radiation effects.
The purpose of the present study was to define the long-term tumor control rates and risks of SRS in patients with newly diagnosed, residual, or recurrent nonfunctional pituitary adenomas. This report expands our earlier series and increases the length of follow-up. 11 
PATIENTS AND METHODS

Patient Population
Between December 1987 and December 2009, 142 consecutive patients underwent Gamma Knife SRS for the treatment of nonfunctional pituitary adenoma at the University of Pittsburgh Medical Center. Seventeen patients were excluded from the analysis because of incomplete data or insufficient follow up (, 6 months), leaving a final series of 125 patients.
The patient population consisted of 69 male (55%) and 56 female (45%) patients with a median age of 53.7 years (range, 15.5-88.1 years). The decision to perform radiosurgery was made in patients with residual or recurrent tumors after prior resection and in those with enlarging primary tumors with a higher risk for resection owing to concomitant medical illnesses or advanced age. For residual tumors found on postoperative imaging, we prefer to perform SRS rather than simple observation, particularly in patients with tumors showing regional invasion or histological features heralding a more aggressive behavior.
Stereotactic radiosurgery was applied as a primary therapeutic modality in 15 patients (12%; median age, 70.1 years; age range, 40.7-88.1 years), for residual tumor in 25 patients (20%) at a median of 4.7 months (range, 1.2-18.8 months) after subtotal resection, or for recurrent tumor that developed after $ 1 resections in 85 patients (68%) at a median of 37.6 months (range, 2.9-218.0 months) after their last operation ( Figure 1 ). Before SRS, 17 patients (13.6%) received FRT after resection to a median dose of 45 Gy (range, 45-56 Gy). The median time interval between the last date of prior radiation therapy and SRS was 62.4 months (range, 16.7-240.9 months). There were 94 tumors (75%) with cavernous sinus involvement and 51 (41%) with suprasellar extension. Of these, 35 adenomas (28%) extended into both the cavernous sinus region and the suprasellar cistern. Three patients had tumor extension into the cavernous sinus bilaterally and underwent 2-stage SRS. At the time of radiosurgery, 43 patients (34.4%) had visual dysfunction, including decreased visual acuity (n = 18), a visual field defect (n = 16), or both (n = 9). Cranial nerve (CN) dysfunction was present in 18 patients (14.4%), including CN III (n = 12), IV (n = 2), V (n = 5), and VI (n = 5). On endocrinological testing, pituitary hormone deficiencies were confirmed in 80 patients (64%). Forty-three (34.4%) patients had 1 or 2 pituitary axis dysfunctions, including thyroidstimulating hormone deficiency (n = 26), adrenocorticotrophic hormone deficiency (n = 13), and sex hormone deficiency (n = 13), and 37 patients (29.6%) had complete anterior pituitary hormone loss. Four patients (3.2%) had posterior pituitary dysfunction and resultant diabetes insipidus controlled with medication (Table 1) .
Stereotactic Radiosurgery
Stereotactic radiosurgery was performed with various models of the Leksell Gamma Knife (U, B, C, 4C, or Perfexion, Elekta, Atlanta, Georgia). The procedure began with cranial application of a model G Leksell stereotactic frame under conscious sedation and local scalp anesthesia. After the stereotactic frame was applied, high-resolution, volume-acquisition stereotactic magnetic resonance images (MRIs) were obtained. In all cases before 1991 or when a patient could not undergo MRI (in case of a pacemaker or MRI-noncompatible aneurysm clip), radiosurgery was performed with computed tomography (CT) guidance. In this series, 7 patients were treated with CT-based SRS. The images were exported to a computer workstation for dose planning with Kula or Gamma Plan software (Elekta, Inc). Dose selection for SRS was based on tumor volume, distance to the optic pathways, and history of previous FRT. The treatment goal was prevention of tumor growth and minimization of treatment-related side effects. The median target volume was 3.5 cm 3 (mean, 4.5 cm 3 ; range, 0.4-28.1 cm 3 ). The median prescription dose delivered to the tumor margin was 13 Gy (mean, 13.9 Gy; range, 10-25 Gy), and the maximum dose varied from 20 to 45 Gy with a median of 26 Gy (mean, 27.9 Gy). The prescription isodose was 50% in 114 cases (91.2%). A median of 7 isocenters (range, 1-17) was used for dose planning. Beam channel blocking was used to limit the radiation dose to the optic apparatus in selected cases. The maximum dose to the visual pathways varied from 3 to 11 Gy (median, 7.7 Gy). All patients received an intravenous dose of 20 to 40 mg methylprednisolone after radiosurgery, and all were discharged from the hospital within 24 hours.
Follow-up
After radiosurgery, all patients were clinically followed up with serial contrast-enhanced MRI or CT, which was requested at 6, 12, and 24 months and then every 2 to 3 years. Imaging follow-up varied from 6 to 223 months with a median of 62 months. Ninety patients (72%) had . 24 months of imaging follow-up, and 64 patients (51.2%) were followed up for . 60 months. The follow-up images were compared with the preirradiation images, and tumor volumes were computed by measuring the maximal anteroposterior, vertical, and horizontal diameters of the lesion in the axial, sagittal, and coronal planes of the MRIs. Tumor volumes were calculated from the volume of an oblate spheroid: (anteroposterior dimension 3 vertical dimension 3 horizontal dimension in cm) 3 (p / 6). In 7 patients who were followed up with CT, vertical dimensions were estimated by the slice thickness of the scan. Given the irregular shape of some tumors, volume measurement should be considered only a rough estimate of the actual tumor volume. Tumor control was defined as tumor reduction (shrinkage of . 50% of the volume) or no change (, 25% increase in size to , 50% shrinkage in volume). Tumor progression was defined as a . 25% increase in volume of the tumor. Patients with tumors not confirmed as having progressed were censored at the time of the last imaging study.
Pituitary function was evaluated at periodic intervals during the follow-up in patients with residual hormonal function. The median endocrine follow-up period was 64 months (ranges, 6.1-181.7 months). Hormonal assessment included measurements of urinary free cortisol excretion and basal serum cortisol, free T4, thyroid-stimulating hormone, luteinizing hormone, follicle-stimulating hormone, prolactin, and insulin-like growth factor-I level. Moreover, testosterone in men and estradiol levels in premenopausal women were also measured. Growth hormone deficiency was diagnosed when there was an insufficient rise in growth hormone levels (absolute value , 3 mg/L) after stimulation during an insulin tolerance test. Secondary hypocortisolism was defined as a basal cortisol level of , 4 mg/dL and/or an insufficient increase in cortisol levels (absolute value , 20 mg/dL) after a corticotrophinreleasing hormone stimulation test or insulin tolerance test. Thyroidstimulating hormone deficiency was defined as a total or free T4 level below the reference range. Gonadotropin deficiency was defined in women by amenorrhea with low plasma estradiol (normal range, , 40 pg/mL) in premenopausal women. Postmenopausal women were defined as gonadotropin deficient when gonadotropin levels were below the normal postmenopausal range (luteinizing hormone , 10 U/L, follicle-stimulating hormone , 30 U/L). In men, gonadotropin deficiency was defined as a testosterone level below the reference range (, 240 ng/dL). Diabetes insipidus was defined as polyuria not reacting to fluid restriction but reacting to the administration of vasopressin.
Neuro-ophthalmological examinations recorded visual acuity and visual fields. Testing was done at our center or at the referring center for patients who lived far from our institution.
Statistical Analysis
Univariate and multivariate analyses were carried out to assess the prognostic value of different variables relative to tumor control, clinical response, and hormonal status. We performed univariate analysis using log-rank test statistics and a stepwise forward likelihood ratio method of Cox proportional hazard models for multivariate analysis. Progression-free survival (PFS) and overall survival time were calculated from the day of SRS with the Kaplan-Meier method. Statistical analysis was performed with SPSS 17 software (SPSS, version 17.0; SPSS, Inc, Chicago, Illinois); values of P , .05 were considered statistically significant.
RESULTS
At the time of this assessment, 113 patients (90.4%) were alive and 12 patients (9.6%) had died. One patient with confirmed tumor progression died of respiratory arrest secondary to a seizure at 15.3 months after radiosurgery. In the remaining 11 patients, the causes of death included malignancy (n = 5), cardiovascular disease (n = 4), and cerebrovascular disease (n = 2), and all occurred at least 12 months after SRS. The average patient survival was 246.3 months (95% confidence interval [CI] = 231.9-260.7) after SRS, and the 5-and 10-year overall survival rates were 92% and 88%, respectively.
Tumor Control
Follow-up imaging studies demonstrated tumor control in 112 patients (89.6%; Figure 2 ). The tumor volume decreased in 66 patients (53%) and remained unchanged in 46 (37%). The median time to tumor reduction was 17.3 months after SRS (range, 3.3-93.8 months). Tumor progression was seen in 13 patients (10.4%), and it was detected at a median of 64 months after SRS (range, 11.2-135.7 months). Two patients had tumor progression outside the radiosurgical treatment volume. In both patients, the treated mass had regressed but a new tumor appeared on the contralateral side of the sella. Both patients underwent In 15 patients treated with SRS as a primary management, 2 patients (13.3%) had progression at 14 and 30 months after SRS, respectively ( Table 2) . Eleven of 110 patients (10%) who had SRS for residual (n = 25) or recurrent (n = 85) tumors showed progression at a median of 64 months after SRS. The type of tumor (new vs residual vs recurrent) did not affect the eventual development of tumor progression (P = .59).
Of the 47 tumors close to the optic apparatus (, 3 mm) that received a median margin dose of 12 Gy (range, 10 -18 Gy), 39 (83%) decreased (n = 14) or remained stable (n = 25) in size. For the 78 tumors having some distance from the optic apparatus (. 3 mm), a median of 14 Gy (range, 10-25 Gy) was delivered, and 73 tumors (94%) showed a reduction (n = 52) or no change (n = 21) in tumor volume. The control rate appeared higher for tumors from the optic pathway, but it was not statistically significant (P = .07).
In univariate analysis, factors associated with shorter PFS included larger tumor volume (either as a continuous variable [P = .002, hazard ratio (HR) = 1.118; 95% CI, 1.041-1.202] or dichotomized to $ 4.5 cm 3 [P = .001]), lower (, 14 Gy) marginal dose (P = .03), and $ 2 prior recurrences (P , .001; Table 3 ). In the entire series, 9 of 40 tumors (22.5%) with a volume of $ 4.5 cm 3 progressed. The median time to progression was 64 months (range, 11.2-102.9 months). In contrast, 4 of the 85 lesions (4.7%) with tumor volumes , 4.5 cm 3 had tumor progression. Kaplan-Meier plots generated for PFS (Figure 4) showed that tumors with a volume $ 4.5 cm 3 had 1-, 5-, and 10-year PFS rates of 97%, 86%, and 49.5%, respectively. Lesions with a volume , 4.5 cm 3 had 1-, 5-, and 10-year PFS rates of 99%, 97%, and 91%, respectively. A tumor volume of , 4.5 cm 3 was significantly associated with longer PFS.
Among 13 patients having $ 2 recurrences before SRS, 5 patients (38.5%) had tumor progression at a median time of 86 months. In contrast, in 72 patients who had only 1 recurrence, 4 patients (5.6%) had progression at a median of 66 months. Patients with 1 recurrence had a 1-, 5-, 10-year PFS rates of 100%, 96%, and 86%, respectively. Patients with $ 2 recurrences had a 1-, 5-, and 10-year PFS rates of 92%, 79%, and 39%, respectively. Thus, patients with $ 2 recurrences before SRS had a shorter PFS ( Figure 5) .
In multivariate analysis, factors associated with shorter PFS included larger ($ 4.5 cm 3 ) tumor volume (P = .04; HR = 5.413) and $ 2 prior recurrences (P = .01; HR = 5.777; Table 3 ).
Clinical Outcomes
After radiosurgery, neurological symptoms or signs, including visual function, improved in 9 patients and eventually worsened (because of either progression of initial symptoms or development of new symptoms) in 6 patients, as shown in Table 4 .
Of the 43 patients harboring visual dysfunction before SRS, 4 patients (9.3%) had improvement of their visual function during follow-up. Four patients (9.3%) experienced a decline in visual field or acuity, and 3 were related to enlarging tumors ultimately requiring repeat resection. One patient who received an 18-Gy margin dose for residual tumor (maximal optic pathway dose, 7.6 Gy) showed a deterioration of visual acuity 18 months after SRS despite tumor regression on imaging. This patient underwent repeat resection and optic decompression.
Among 18 patients with symptoms related to CN dysfunction at the time of radiosurgery, 5 (27.8%) had improvement in their symptoms (diplopia in 3 patients and facial pain in 2 patients). New nonoptic cranial neuropathies developed in 2 patients (1.6%): temporary CN V neuropathy in 1 patient and permanent neuropathies of CNs III and IV in 1 patient. One patient who received a 26-Gy maximum dose experienced left facial sensory symptoms 6 months after radiosurgery despite a tumor size reduction, which resolved 6 months later. Another patient who had harbored a macroadenoma involving the cavernous sinus and had received a 30-Gy maximum dose developed persistent CN III and IV palsies 73 months after radiosurgery despite no definite change in tumor volume.
Symptomatic deteriorations resulting from either aggravation of visual symptoms or development of new CN symptoms were significantly more common in patients with tumor progression as opposed to tumor control (P = .02).
Hormonal Outcomes
Of the 88 patients with residual pituitary hormonal function at the time of SRS, 21 (24%) developed $ 1 new pituitary axis deficits at a median of 64 months (range, 6.1-181.7 months) of hormonal follow-up (Table 4) 
, and 10 years was 6%, 13%, 29%, and 48% ( Figure 6 ). One patient with secondary hypothyroidism experienced an improvement of thyroid function at 24 months after SRS, leading to cessation of thyroid hormonal replacement.
In univariate analysis, prior radiation therapy (P = .03) and older age (P = .05) were associated with an increased likelihood of developing a new pituitary hormone deficit. The 2-and 5-year risks for developing a new hormonal deficit in patients receiving radiation therapy before SRS were 23% and 77%, respectively, and the risks in those who did not have prior radiation therapy were 12% and 23%, respectively ( Figure 7 ). For patients $ 55 years of age, the 2 and 5-year risks of developing new pituitary deficits were 17% and 41% compared with 10% and 18% for younger patients (P = .05). After age adjustment, prior radiation therapy was noted to be an independent factor for the development of a new hormonal deficit after radiosurgery (P = .04; HR = 2.975; 95% CI = 1.082-8.179; Table 5 ).
For patients who were naïve to radiation therapy, the actuarial risk of pituitary deficits at 1, 2, 5, and 10 years was 5%, 12%, 23%, and 47%.
DISCUSSION
Nonfunctional pituitary adenomas often present with symptoms and signs relating to local mass effect, including headache, visual disturbances, or pituitary insufficiency. Surgical resection is the initial treatment of choice for most symptomatic patients with nonfunctional pituitary adenomas. It provides the advantages of pathological confirmation and decompression of the optic apparatus and adjacent pituitary gland and facilitates rapid recovery.
12, 13 Chang et al 14 analyzed the outcomes of 663 patients with nonfunctional pituitary tumors over a 20-year period who underwent surgery alone or in combination with radiotherapy. They found that gross total resection was an important prognostic factor for long-term cure and that adjuvant FRT did not provide benefit for patients undergoing gross total resection. However, many pituitary tumors involve the cavernous sinus, suprasellar cistern, or middle fossa, 12, [14] [15] [16] which makes the achievement of complete resection variable (46%-75% of all surgical cases).
12-14
The long-term recurrence rate after surgery alone has been noted in 50% to 85% of cases. 6, 7, [17] [18] [19] Conventional FRT has commonly been used to halt the regrowth of residual tumors and to prevent new neurological symptoms. In Table 6 , we summarize 4 previous studies that evaluated the effects of long-term follow-up after transsphenoidal surgery, with and without postoperative radiotherapy, on tumor control of nonfunctional pituitary adenomas. 6 7 who found that the 10-year PFS rate was 95% for patients receiving early postoperative radiation therapy compared with 22% of patients observed without radiotherapy. Despite enhanced tumor control, FIGURE 7. Kaplan-Meier new hormonal deficit curves demonstrating effect of prior radiation therapy (RTx). Prior radiation therapy was associated with a higher rate of new hormonal deficit ( P = .03).
several concerns are associated with conventional FRT. It has a 1% to 7% risk of delayed optic neuropathy 5, [21] [22] [23] [24] and a 50% to 100% rate of long-term pituitary hormone deficiency. [24] [25] [26] The actuarial incidence of a stroke after FRT is 4.1% at 5 years. 27 In addition, pituitary adenoma patients have a reported cumulative risk of 1.9% to 2.7% at 10 to 30 years for the development of a radiation-related neoplasm. 5, 26, [28] [29] [30] Stereotactic radiosurgery delivers a high single procedural radiation dose to a target volume with a steep boundary gradient to minimize effects on surrounding normal tissues. The radiobiological effect of this single dose to divide tissue slowly provides a unique radiobiological advantage compared with multisession FRT. Nishioka et al 31 analyzed the histopathological changes of pituitary adenoma specimens after either radiosurgery or FRT. They found that SRS-treated specimens showed more intense histological changes, including hyaline deposition and central necrosis.
Recent publications related to SRS for nonfunctional pituitary tumors show tumor control rates that range from 87% to 97% and regression rates from 42% to 78%. 9, 11, [32] [33] [34] [35] [36] In the present study, the tumor control rate was 89.6% at a median of 62 months of follow-up. Fifty-three percent of tumors showed a tumor volume reduction (.50%), and 37% were stable. Tumor recurrences developed in 13 patients (10.4%) at a median time to progression of 64 months after radiosurgery. We found that larger tumors were more likely to progress despite SRS. The 5-and 10-year PFS rates were 97% and 91%, respectively, for patients with a tumor volume ,4.5 cm 3 and 86% and 49.5% for those $ 4.5 cm 3 . A target volume of , 4.5 cm 3 was an independent factor for better PFS (P = .04; HR = 5.413; 95% CI = 1.060-27.641).
Mingione et al 34 analyzed the outcomes of 90 evaluable patients with nonfunctional pituitary adenoma undergoing SRS. Among the 8 patients who underwent Gamma Knife SRS as the primary approach, shrinkage in tumor volume occurred in 3; 5 patients were unchanged at a mean follow-up period of 34 months (tumor control rate, 100%). In our series, 15 patients with advanced age or significant surgical risks underwent SRS as the primary therapeutic option, and tumor control was achieved in 13 patients (86.7%). In our experience, we found no difference in tumor control between unoperated nonfunctional pituitary adenomas and residual or recurrent tumors (P = .59). These results support a potential role for SRS as a primary therapy in selected patients with enlarging primary tumors during a period of observation with a higher risk for resection resulting from concomitant medical illnesses or advanced age. However, the absence of a histological diagnosis is a limitation of this treatment strategy. Considering a low risk of transsphenoidal surgery performed by an experienced surgeon, we advocate surgical resection as the first approach in patients with acceptable surgical risks. The radiosurgical doses selected for nonfunctional pituitary adenomas are usually lower than the doses deemed necessary for functional adenomas. However, the optimal dose for a nonfunctional pituitary tumor remains unclear. Losa et al 33 demonstrated that the radiation dose applied to the periphery of the tumor had been significantly higher in patients who experienced tumor reduction compared with patients who had no change in volume (17.4 6 0.5 vs 15.9 6 0.5 Gy). In our previous study, we noted that a margin dose of 13 to 14 Gy was effective. 11 Recently, Mingione et al 34 reported that the lowest effective marginal dose was 12 Gy and that doses .20 Gy did not improve the tumor control rates. In the present study, lower radiation dose to the tumor margin (# 13Gy) was demonstrated to be a significant risk factor for recurrence by univariate analysis (P = .03). However, this did not remain significant in multivariate testing (P = .89). The dose selection for a pituitary tumor is dependent on tumor volume, the time interval between prior FRT and SRS, and the distance from the tumor margin to the optic apparatus. In patients with tumors adjacent to the optic nerve or chiasm, we usually used a relatively low dose of 10 to 12 Gy for the tumor margin, keeping the maximal optic pathway dose of #10 Gy, especially for the patient retaining visual function. In 47 patients with pituitary tumors close to the optic pathway (,3 mm), we achieved an 83% tumor growth control rate, comparable to the 94% for tumors at a greater distance from the optic apparatus. Iwai et al 32 noted that growth control was observed in 86.7% of nonfunctional pituitary tumors that were adjacent to or compressed the optic apparatus. They did not find a difference in tumor growth control according to the distance to the optic apparatus. They noted that if most of the tumor received a sufficient dose, tumor growth control could be achieved even in tumors that adhere to or are in close proximity to critical surrounding structures.
The most frequent side effect of SRS for nonfunctional pituitary tumors is hypopituitarism, which has been reported in 0% to 28% with a limited mean or median follow-up of 21 to 98 months. 9, 11, [32] [33] [34] [35] [36] In a study by Pollock et al, 9 the risk of developing a hormonal deficit at 5 years after SRS was 32%; for tumors # 4 cm 3 , the risk was 18% compared with 50% if the tumor volume was . 4 cm 3 . Recently, Leenstra et al 37 found a correlation between the pituitary gland radiation dose and the incidence of new hormonal deficits after SRS. In our series, a new pituitary hormonal deficit was identified in 24% of patients at a median of 24 months. The actuarial risks of developing new pituitary deficits at 5 and 10 years were 29% and 48%, respectively. Older patients ($ 55 years of age) and those with a history of prior radiation therapy were more likely to develop pituitary hormone loss. Hypopituitarism is most often recognized 5 to 10 years after FRT but may develop up to 20 years afterward. 1, 5, 25, 26, 30 Considering the median interval between prior FRT and SRS of 62.4 months (range, 16.7-240.9 months), new hormonal deficits in this series may have originated in part from prior radiation therapy. In addition, pituitary hormonal deficits may result in part from aging itself. A controlled, longterm study focusing on this issue is needed to determine the incidence of radiosurgery-induced hypopituitarism.
Neurological side effects such as visual dysfunction or cranial neuropathy are also reported after SRS. Optic neuropathy generally occurs within 2 years of radiosurgery, and the incidence is reported to be 2% to 5%. [38] [39] [40] Generally, , 8 Gy was recommended as the limiting dose to the optic pathway in SRS. 38 More recently, it has been suggested that a small volume of the optic apparatus as high as 10 Gy may be exposed without a significantly increased risk of optic neuropathy. 39, 41 In our study, 1 patient (0.8%) had visual deterioration 18 months after SRS, even though the dose to the optic apparatus was , 7.6 Gy.
New CN deficits were noted in 2 patients (1.6%) in our series. The maximal doses delivered to the tumors were 26 and 30 Gy, respectively. It has been shown that CNs of the cavernous sinus could be safely irradiated with a dose up to 40 Gy. 38 Therefore, cranial neuropathy could be caused either by compression of the nerve by transient tumor edema or by stretching or scarring as part of tumor regression. 42 Nine patients had an improvement of their neurological symptoms after SRS (vision in 4 patients and cranial neuropathy in 5 patients). Although the main goal of SRS is not symptom control, postradiosurgery improvement in CN function, including vision, has been reported in a small number of patients. 11, [43] [44] [45] [46] [47] Despite a variety of advantages of single-session SRS, use of this innovative technique for pituitary adenomas may be limited by tumor size or proximity to the optic apparatus. Recently, fractionated stereotactic radiotherapy has been used in an attempt to reduce radiation injury to the surrounding critical structures and to be able to make the radiation field broader. It provides imageguided, usually frameless, fractionation without the need to reacquire imaging and treatment planning at each treatment session. Several published series have shown comparable efficacies of fractionated stereotactic radiotherapy and other radiation techniques, with tumor control, hormonal deficiency, and visual complications of 92% to 100%, 0% to 15%, and 0% to 8%, respectively. [48] [49] [50] Proton beam therapy is another promising modality; it allows conformal dosimetry (compared with conventional radiotherapy) without exit dose delivery beyond the target volume, although outcome data from sufficiently large series are lacking. 51 Although there are no prospectively acquired comparison data on efficacy and safety of radiosurgery vs radiotherapy, for patients with larger tumors that, despite resection, continue to envelope the optic nerve or chiasm, we believe that FRT remains valuable. In patients in whom the tumor can receive an effective dose and the nerve can receive a tolerable dose, even in close proximity, we prefer radiosurgery.
The optimal time to perform SRS, FRT, or fractionated stereotactic radiotherapy for nonfunctional pituitary tumors remains unknown. Van den Bergh et al 7 addressed the importance of early postoperative radiotherapy in the case of residual tumors. They demonstrated that immediate adjuvant radiotherapy resulted in long-lasting local control without an additional harmful effect on pituitary function and life expectancy. In contrast, Dekkers et al 20 reported in their observational study that even in the case of residual tumors, no tumor regrowth was observed in 87% during a median of 5 years of follow-up. From these data, the authors suggested a postsurgical wait-and-see procedure, which could prevent unnecessary exposure to potential sequelae of radiotherapy in the majority of patients. Similarly, Chang et al 14 noted that adjuvant radiation therapy can be deferred until recurrence is documented on surveillance because not all patients with residual tumors experience progression, and progression is typically delayed. The possible benefit of postoperative irradiation has to be balanced against the potential side effects of irradiation. Therefore, the decision of whether to perform SRS for residual or recurrent nonfunctional pituitary adenomas must be individualized, taking into account the size and location of the remnant and the patient's age, pituitary hormonal status, and comorbidities. Comtois et al 52 represented a significantly higher rate of recurrence in patients with invasive tumors after surgical resection. Losa et al 53 reported a relative risk of 10.5 for tumor recurrence when invasion of the cavernous sinus was identified by MRI. Several other factors, including younger age, tumor size, oncocytoma variant tumor, subtotal resection, and previous pituitary surgery, also are reported to be associated with higher recurrence rates. 5, 14, 19, [53] [54] [55] The proliferative index of the pituitary adenoma also has been studied as a potentially significant predictor of recurrence. 54, 56 In our series, we found that tumor control rates for residual and recurrent tumors were 92% and 89.4%, respectively. However, patients with $ 2 recurrences had a 61.5% tumor control rate compared with 94.4% for patients with a single recurrence. We consider SRS in selected patients with hypopituitarism and large residual tumors that are invasive of regional structures or whose histological features suggest a more aggressive behavior.
CONCLUSION
In this clinical experience with an extended follow-up, we found that Gamma Knife SRS is an effective and relatively safe means of managing residual or recurrent nonfunctional pituitary adenoma after resection. Patients who have a residual tumor are optimal candidates for SRS, especially when they have a risk factor for recurrence. The procedure is also valuable in treating newly diagnosed tumors in patients who have unacceptable risk factors for microsurgery. Tumors adjacent to the optic pathway can be treated effectively with current strategies that restrict the optic apparatus dose. We believe that our data provide additional long-term evidence that SRS is a safe and effective strategy that improves the treatment options and outcomes for progressive nonfunctional pituitary adenomas.
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for a suboptimal resection, and the strategy of "debulk and radiate" must be strongly advocated against. In my practice, I now routinely see patients offered SRS as a ''first-line'' therapy after suboptimal surgery and in some cases as an upfront treatment option. I suspect that this trend is due to a combination of the proliferation of radiosurgery units and the many publications that report the extremely high tumor control rates like those reported by Park et al. Pituitary adenomas should not be considered in the same category as other benign neoplasms that can be controlled with SRS. The development of hormonal deficits can dramatically worsen quality of life and increases morbidity and mortality. This often has a far greater impact on patients than a small degree of tumor progression. Therefore, although I laud the authors for their excellent and accurate analysis of their long-term data, I feel that SRS should be reserved for a very limited subset of patients with recurrent and symptomatically progressive pituitary tumors.
Adam N. Mamelak Los Angeles, California T he group at the University of Pittsburgh continues to contribute long-term data on patients treated with radiosurgery for nonfunctioning pituitary adenomas. The careful follow-up for complications and local control is extended in this large, consistently treated group of patients.
It is clear that the roles of microsurgery via less invasive transsphenoidal approaches have made interval improvements in the ability to resect and to create diminished complications for pituitary adenomas. Stereotactic radiosurgery clearly offers the greatest potential to similarly limit the volume of normal tissues treated with radiation. Insofar as the tumor target may be clearly identified, the advantage of radiosurgery is clear. The results after a single surgery appear outstanding, perhaps because of the improved clarity with which targets might be identified. It is interesting that after $ 2 recurrences the control rate is diminished. Part of the issue here may be that the target definition is clouded by several surgical interventions that make target identification less clear. This may be an area in which larger field fractionation might be in order. The attempts to reduce the field size may negatively affect overall control.
In addition, it is interesting to consider the potential roles for and continuous evolution of fractionated radiation in light of improvements in stereotactic radiosurgery. Although radiosurgery has substantial advantages for smaller lesions that are well defined, there are certainly cases in which volumes are excessively large for radiosurgical intervention. Unfortunately, these cases may require larger field techniques for which fractionation is helpful.
It is also noteworthy that when lesions are essentially attached to the optic apparatus, it is not clearly advisable to deliver marginal doses of 12 Gy that would directly hit this optic apparatus. The doses need to be kept low, as is discussed well by the authors, and the decision as to when a dose is safe requires significant care. Such cases may also suggest a role for fractionated stereotactic therapy.
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